Cancer of Lung Clinical Trial
Official title:
Effect of 3D-printed Reconstruction Automated Matching System in Selecting the Size of Left Double-lumen Tube
The precise and accurate size of DLT is a prerequisite to ensure its accurate position of its placement. Three-dimensional (3D) reconstruction technology can accurately reproduce the tracheobronchial structure to improve the correct size selection of DLT. To make it simpler, the investigators developed an automatic comparison software for 3D reconstruction based on computed tomography data (3DRACS). In this study, the investigators aimed to prove that 3DRACS is much more efficient in endobronchial intubation compared to the traditional method.
Status | Not yet recruiting |
Enrollment | 200 |
Est. completion date | July 30, 2024 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Aged between 18 and 75 years. 2. American Society of Anesthesiologists Physical Status (ASA-PS) I-III. 3. Planned to receive lung resection surgery during lung isolation techniques by using DLT. 4. Signed informed written consent. Exclusion Criteria: The participant experiences any of the following: 1. Spinal malformation, 2. Expected difficult airway 3. Tracheal stenosis 4. Tracheal tumor 5. Bronchial tumor 6. Distorted airway anatomy 7. Tumors of the mouth or neck |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sichuan Cancer Hospital and Research Institute |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the success rates of placement of left DLT without FOB | Conventional blindly endobronchial intubation is performed firstly and clinical verification was made by the same anesthesiologist, followed by the supervising anesthesiologist using a FOB to check DLT position and successful intubation was considered if the position was proper. | After intubation,an average of 2 hours | |
Secondary | The time of completing the left DLT's position | There are two different situations that we need to describe. First, it starts from the cuff of left DLT crosses the vocal cords, and stops when the left DLT position succeeds without FOB(attempts=3). A stopwatch is used for this purpose, where it is ON when the cuff of left DLT crosses the vocal cords and stops when intubating anesthesiologist considers the left DLT is correctly positioned. Second, it starts from the cuff of left DLT crosses the vocal cords and stops when positioning successfully with FOB after three attempts all fail. Each attempt is defined as returning the bronchial lumen of the left DLT to the trachea and then attempting to reinsert it. | After intubation,an average of 2 hours | |
Secondary | The number of the patients who need to change the size of the left DLT | If the position of the left DLT under the FOB guidance doesn't match and the intubation fails because of the improper size of the left DLT, we need to change another left DLT. | After intubation,an average of 2 hours | |
Secondary | Appropriate standard for the left DLT | Objective criteria is injecting air into the cuff. When the pressure inside the left DLT is 25 mmHg, it will be stopped and connected to the anesthesia machine. And the air leakage phenomenon is adjusted when the peak pressure is lower than 30 cm H2O. Oversized left DLT is defined that good pulmonary isolation could be achieved by injecting <1 ml of air into the bronchial cuff and <2 ml of air into the main tracheal cuff, while more than 3 or 6 ml of air into the two cuff is defined undersized left DLT. | After intubation,an average of 2 hours | |
Secondary | Lung collapse | Ten and 20 min after pleurotomy, the degree of pulmonary atrophy is assessed by a chest surgeon unaware of the grouping with an eleven-point Likert scale with 0 marked as no pulmonary atrophy at all and 10 as most perfect lung collapse. | At 10 and 20 minute after pleurotomy | |
Secondary | Grading of the airway injury | it will be done by a trained anesthesiologist with over 10 years of FOB experience, The severity of the tracheal injury is defined as mild (redness, edema, one to three speckled hemorrhagic lesions), moderate (over 3 mild lesions or one diffuse hemorrhagic lesion), and severe (more than 2 diffuse hemorrhagic lesions) The type of lesions in vocal cords is classified into edema with inflamed mucosa, petechiae (small red spots on the mucosa), and hematoma (bleeding into the mucosa). | After extubation,an average of 1 hours | |
Secondary | Postoperative sore throat and hoarseness | they are defined as persistent resting pain in the throat region, where throat pain scores are assessed using VAS score i.e., 0 for no pain, and 10 for unbearable pain, while hoarseness is defined as a change in the quality of voice observed by the patient. | 1, 2 days after surgery | |
Secondary | Oxygenation during one-lung ventilation | it is defined as the area under the curve of the SpO2/FiO2 ratio during OLV. The SpO2 and FiO2 values are automatically collected by the monitor at 30-second intervals and any abnormal data due to equipment or human error is replaced with the previous correct data. | At the end of surgery. | |
Secondary | Times of using FOB | The times of using FOB guiding to place the left DLT correctly after three attempts all fail. | At the end of surgery. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01860898 -
A Phase I Study of iPS Cell Generation From Patients With COPD
|
N/A | |
Completed |
NCT05011890 -
Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare®
|
N/A | |
Active, not recruiting |
NCT02931942 -
Changing Over Time of Ascorbic Acid After Chemotherapy
|
||
Completed |
NCT02616211 -
An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
|
||
Active, not recruiting |
NCT04300244 -
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
|
Phase 2 | |
Enrolling by invitation |
NCT05844761 -
Real-time Motion Management During Prostate and Lung Radiotherapy
|
N/A | |
Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
Terminated |
NCT02673021 -
MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)
|
N/A | |
Terminated |
NCT03603652 -
NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung
|
N/A | |
Not yet recruiting |
NCT05857995 -
Precision Lung Cancer Survivorship Care Intervention
|
N/A | |
Completed |
NCT03102229 -
Real-time Activity Monitoring to Prevent Admissions During RadioTherapy
|
N/A | |
Recruiting |
NCT04699188 -
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
|
Phase 1/Phase 2 | |
Completed |
NCT02853188 -
Measure of Plasma Tissue Factor to Predict a Venous Thromboembolism in Primitive Cancer of Lung
|
N/A | |
Completed |
NCT02410603 -
Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer
|
||
Completed |
NCT00328588 -
LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy
|
Phase 2 | |
Recruiting |
NCT02549638 -
Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
|
||
Completed |
NCT02370303 -
A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
|
||
Completed |
NCT01470248 -
Study of Arsenic Trioxide in Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04717804 -
4D CBCT and Intrafractional Imaging for the Determination of the Most Representative 4D Simulation Planning Technique for Lung SBRT Technique Patients
|
N/A | |
Recruiting |
NCT04263467 -
High Intensity Aerobic Exercise Training and Immune Cell Mobilization in Patients With Lung Cancer (HI AIM)
|
N/A |